Photo from wikipedia
Current guidelines strongly recommend the utilization of cisplatin-based neoadjuvant chemotherapy (NAC) for patients with muscle-invasive bladder cancer (MIBC) [1]. However, neoadjuvant systemic therapy is still underutilized due to cisplatin-ineligibility of… Click to show full abstract
Current guidelines strongly recommend the utilization of cisplatin-based neoadjuvant chemotherapy (NAC) for patients with muscle-invasive bladder cancer (MIBC) [1]. However, neoadjuvant systemic therapy is still underutilized due to cisplatin-ineligibility of approximately half of the patients, fear of prohibitive adverse events and/or delay of therapy in non-responders. NAC has, nonetheless, many potential benefits in the management of non-metastatic MIBC.
Journal Title: BJU International
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!